DSM Expands Industrial Biocatalysis Platform With c-LEcta Agreement

PARSIPPANY, N.J. and LEIPZIG, Germany, Dec. 15 2010 /PRNewswire/
— DSM Pharmaceutical Products, the custom manufacturing
organization of Royal DSM NV, today announces a license agreement
with c-LEcta GmbH for proprietary screening technology.

The agreement grants DSM rights to c-LEcta’s proprietary alcohol
dehydrogenases for enzyme screening programs and development of
sustainable manufacturing routes for manufacturing of
pharmaceutical active ingredients and intermediates. Germany-based
c-LEcta is an industrial biotechnology company developing and
implementing sustainable and economic industrial processes based on
customized enzymes and microbial production strains.

Based on its patent-protected technology platform for the
identification and optimization of biocatalysts, cLEcta has built
up a unique collection of several hundred enzymes and qualified
enzyme mutants. Alcohol dehydrogenases make up one of the important
enzyme classes in this field and can be used for the cost efficient
synthesis of chiral alcohols from ketones with extraordinary
purities.

DSM applies their InnoSyn™ route scouting to identify more
cost efficient routes for the development and manufacture of drug
intermediates and ingredients by combining biocatalytic solutions
with advanced chemical and process technologies. The new routes
result in shorter cycle times due to fewer steps in the process
with the same reliability and quality using more renewable starting
materials. DSM, a global leader in industrial biocatalysis,
continuously broadens its enzyme platforms by in-house developments
and partnering models with innovative biotech companies such as
c-LEcta.

Dr. Oliver May, Business Manager for DSM comments: “This
agreement further broadens our alcohol dehydrogenase platform which
we set up for rapid screening programs for our customers and the
development of cost efficient production of a large spectrum of
chiral secondary alcohols.”

DSM wil

‘/>”/>

SOURCE